Ignite Creation Date:
2025-12-25 @ 4:24 AM
Ignite Modification Date:
2026-03-02 @ 4:23 PM
Study NCT ID:
NCT02865720
Status:
COMPLETED
Last Update Posted:
2021-06-02
First Post:
2016-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D054179', 'term': 'Angioedemas, Hereditary'}], 'ancestors': [{'id': 'D000799', 'term': 'Angioedema'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D000081208', 'term': 'Hereditary Complement Deficiency Diseases'}, {'id': 'D000081207', 'term': 'Primary Immunodeficiency Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D014581', 'term': 'Urticaria'}, {'id': 'D017445', 'term': 'Skin Diseases, Vascular'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C469952', 'term': 'SERPING1 protein, human'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTransparency@shire.com', 'phone': '+1 866 842 5335', 'title': 'Study Director', 'organization': 'Shire'}, 'certainAgreement': {'otherDetails': 'If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From start of study drug administration up to Week 12', 'eventGroups': [{'id': 'EG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 7, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Intervertebral disc disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 3, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Seasonal allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Herpes virus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Ligament sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Cervicobrachial syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Device failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Product Issues', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Breast disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}], 'seriousEvents': [{'term': 'Hereditary angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study drug administration up to Week 12', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with the treatment. TEAEs were defined as all AEs that started during the treatment period and up to 7 days after the last dose of investigational product, or AEs that were seen at baseline but worsened in frequency and/or severity during the treatment period and up to 7 days after the last dose of investigational product.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT-S set included participants who received any amount of investigational product.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Clinically Significant Abnormalities in Physical Examination Reported as Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study drug administration up to Week 12', 'description': 'Physical examinations included measurement of body weight and height. Clinically significant abnormalities related to physical examination as determined by investigator were recorded and reported as AE.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT-S set included participants who received any amount of investigational product.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Potentially Clinically Important (PCI) Vital Signs Reported as Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 12', 'description': "Vital sign assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate. Investigator used both absolute values and change from baseline values to determine if the vital sign was potentially clinically important. Criteria for the potential clinical importance of both absolute and change from baseline values were pre-specified as: SBP (less than \\[\\<\\] 90 millimeter of mercury \\[mmHg\\]; greater than or equal to \\[\\>=\\] 140 mmHg), DBP (\\< 60 mmHg; \\>=90 mmHg) and pulse (less than or equal to \\[\\<=\\] 50 beats per minute \\[bpm\\]; \\>= 100 bpm. A participant's vital sign had to meet both the absolute and change from baseline criteria to be considered as potentially clinically important.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT-S set included participants who received any amount of investigational product.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Potentially Clinically Important (PCI) Clinical Laboratory Assessments Reported as Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 12', 'description': 'Number of participants with potentially clinically important (PCI) clinical laboratory assessments reported as adverse events were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT-S set included participants who received any amount of investigational product.'}, {'type': 'PRIMARY', 'title': 'Concentration of C1 Esterase Inhibitor (C1 INH) Antigen (Protein Volume) at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0581', 'spread': '0.04877', 'groupId': 'OG000'}]}]}, {'title': '0.5 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1463', 'spread': '0.04210', 'groupId': 'OG000'}]}]}, {'title': '1 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1426', 'spread': '0.05795', 'groupId': 'OG000'}]}]}, {'title': '2 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1436', 'spread': '0.04524', 'groupId': 'OG000'}]}]}, {'title': '6 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1413', 'spread': '0.04376', 'groupId': 'OG000'}]}]}, {'title': '24 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1147', 'spread': '0.03825', 'groupId': 'OG000'}]}]}, {'title': '48 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0978', 'spread': '0.04204', 'groupId': 'OG000'}]}]}, {'title': '72 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0881', 'spread': '0.04133', 'groupId': 'OG000'}]}]}, {'title': '96 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0680', 'spread': 'NA', 'comment': 'Standard Deviation is not calculated due to a single participant being evaluable.', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 1: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 hours (h) post-dose', 'description': 'C1 INH antigen concentration in plasma was determined using an automated nephelometric assay.', 'unitOfMeasure': 'Gram per liter (g/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) set included all participants with evaluable PK profiles.'}, {'type': 'PRIMARY', 'title': 'Concentration of C1 Esterase Inhibitor (C1 INH) Antigen (Protein Volume) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0775', 'spread': '0.04904', 'groupId': 'OG000'}]}]}, {'title': '0.5 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1660', 'spread': '0.04159', 'groupId': 'OG000'}]}]}, {'title': '1 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1468', 'spread': '0.03232', 'groupId': 'OG000'}]}]}, {'title': '2 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1634', 'spread': '0.04500', 'groupId': 'OG000'}]}]}, {'title': '6 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1573', 'spread': '0.03978', 'groupId': 'OG000'}]}]}, {'title': '24 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1244', 'spread': '0.04675', 'groupId': 'OG000'}]}]}, {'title': '48 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1003', 'spread': '0.05030', 'groupId': 'OG000'}]}]}, {'title': '72 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0836', 'spread': '0.05169', 'groupId': 'OG000'}]}]}, {'title': '96 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0661', 'spread': '0.05163', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'C1 INH antigen concentration in plasma was determined using an automated nephelometric assay.', 'unitOfMeasure': 'gram per liter (g/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK set included all participants with evaluable PK profiles.'}, {'type': 'PRIMARY', 'title': 'Concentration of Plasma Complement C4 at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '42.8', 'spread': '20.42', 'groupId': 'OG000'}]}]}, {'title': '0.5 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '37.5', 'spread': '17.55', 'groupId': 'OG000'}]}]}, {'title': '1 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '32.7', 'spread': '18.17', 'groupId': 'OG000'}]}]}, {'title': '2 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '43.3', 'spread': '19.48', 'groupId': 'OG000'}]}]}, {'title': '6 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '69.0', 'spread': '29.70', 'groupId': 'OG000'}]}]}, {'title': '24 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '89.0', 'spread': '33.80', 'groupId': 'OG000'}]}]}, {'title': '48 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '82.5', 'spread': '36.00', 'groupId': 'OG000'}]}]}, {'title': '72 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '80.5', 'spread': '41.34', 'groupId': 'OG000'}]}]}, {'title': '96 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '67.0', 'spread': 'NA', 'comment': 'Standard Deviation is not calculated due to a single participant being evaluable.', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 1: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'Concentration of plasma complement C4 was reported.', 'unitOfMeasure': 'Milligram per liter (mg/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacodynamic (PD) set included all participants with evaluable PD profiles.'}, {'type': 'PRIMARY', 'title': 'Concentration of Plasma Complement C4 at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '77.9', 'spread': '37.79', 'groupId': 'OG000'}]}]}, {'title': '0.5 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '65.0', 'spread': '37.92', 'groupId': 'OG000'}]}]}, {'title': '1 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '41.4', 'spread': '13.79', 'groupId': 'OG000'}]}]}, {'title': '2 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '67.5', 'spread': '40.19', 'groupId': 'OG000'}]}]}, {'title': '6 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '91.1', 'spread': '49.98', 'groupId': 'OG000'}]}]}, {'title': '24 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '104', 'spread': '53.35', 'groupId': 'OG000'}]}]}, {'title': '48 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '99.3', 'spread': '50.65', 'groupId': 'OG000'}]}]}, {'title': '72 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '77.9', 'spread': '47.39', 'groupId': 'OG000'}]}]}, {'title': '96 h post-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '63.2', 'spread': '37.06', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'Concentration of plasma complement C4 was reported.', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PD set included all participants with evaluable PD profiles.'}, {'type': 'PRIMARY', 'title': 'Concentration of Plasma Complement C1q at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '78.50', 'spread': '36.598', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 1)', 'description': 'Concentration of plasma complement C1q was reported.', 'unitOfMeasure': 'International units per milliliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PD set included all participants with evaluable PD profiles.'}, {'type': 'PRIMARY', 'title': 'Normalized Number of Angioedema Attacks (NNA) Per Month', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Historical', 'categories': [{'measurements': [{'value': '3.375', 'spread': '2.5225', 'groupId': 'OG000'}]}]}, {'title': 'CINRYZE Treatment', 'categories': [{'measurements': [{'value': '1.826', 'spread': '1.5031', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'Angioedema attack was defined as any participant-reported (or caregiver-reported) indication of swelling or pain at any location following a report of no swelling or pain on the previous day (that is, there must have been a full symptom-free calendar day preceding the onset of symptoms for an attack to be considered a new attack). NNA was calculated as the overall number of angioedema attacks recorded during the period divided by the number of days in the period and multiplied by 30.4.Number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency as compared to the historical data where, NNA was the number of angioedema attacks during 3 months prior to study drug administration. Historical data was obtained from medical or angioedema history electronic case report forms (eCRF).', 'unitOfMeasure': 'Angioedema attacks per month', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Angioedema Attacks in Different Anatomic Locations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Abdominal/Gastrointestinal: H', 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}]}]}, {'title': 'Abdominal/Gastrointestinal: T', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}]}]}, {'title': 'Cutaneous - Facial: H', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}]}]}, {'title': 'Cutaneous - Facial: T', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Cutaneous - Extremity or Peripheral: H', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}, {'title': 'Cutaneous - Extremity or Peripheral: T', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}, {'title': 'Genital/Urinary (Includes scrotum or vulva): H', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Genital/Urinary (Includes scrotum or vulva): T', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Upper Airway (includes laryngeal or pharyngeal): H', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Upper Airway (includes laryngeal or pharyngeal):T', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 12', 'description': "Anatomic locations where there was a presence of pain or swelling of any level of severity; mild, moderate or severe at any day during the attack were reported. Mild: the attack symptoms were noticeable but were easily tolerated by the participant and did not interfere with the participant's daily activities. Moderate: the attack symptoms interfered with the participant's ability to attend work/school or participate in family life and social/recreational activities and severe: the attack symptoms significantly limited the participant's ability to attend work/school or participate in family life and social/recreational activities. Number of participants with angioedema attacks in different anatomic locations in treatment period was compared to NNA for historical data. Historical data was based on the typical location of angioedema attacks in the 3 months prior to study drug administration. Here, H refers to historical and T refers to treatment.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Average Severity (Intensity) of Angioedema Attacks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Historical', 'categories': [{'measurements': [{'value': '1.875', 'spread': '0.8345', 'groupId': 'OG000'}]}]}, {'title': 'CINRYZE Treatment', 'categories': [{'measurements': [{'value': '0.970', 'spread': '0.6441', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the participant to any swelling location on any day during the attack. The average severity was derived by dividing the cumulative severity score by the total number of attacks. Average severity was set to 0 if there was no attack in a period. Average severity of angioedema attacks in treatment period compared to the NNA of angioedema attacks for historical data was reported. Historical data was based on the typical severity of angioedema attacks in the 3 months prior to study drug administration. Historical data was obtained from medical or angioedema history electronic case report forms (eCRF).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 postbaseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Average Duration of Angioedema Attacks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Historical', 'categories': [{'measurements': [{'value': '2.250', 'spread': '1.0351', 'groupId': 'OG000'}]}]}, {'title': 'CINRYZE Treatment', 'categories': [{'measurements': [{'value': '1.941', 'spread': '2.0630', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'Average duration of attacks was calculated by dividing the cumulative duration of attacks by the total number of attacks during the treatment period. Historical data was based on the typical severity of angioedema attacks in the 3 months prior to study drug administration. Average duration of angioedema attacks in treatment period was compared to the NNA for historical data. Historical data was obtained from medical or angioedema history eCRF.', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Normalized Number of Angioedema Attacks (NNA) Per Month Treated With Rescue Medication', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Historical Data', 'categories': [{'measurements': [{'value': '1.750', 'spread': '2.2660', 'groupId': 'OG000'}]}]}, {'title': 'CINRYZE Treatment', 'categories': [{'measurements': [{'value': '0.477', 'spread': '0.8411', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'The normalized number of angioedema attacks was calculated as the overall number of angioedema attacks recorded during the period divided by the number of days in the period and multiplied by 30.4. NNA treated with rescue medications were reported for CINRYZE, non-CINRYZE C1-INH or not treated with C1-INH (including attacks treated with any medications other than C1-INH or untreated attacks). CINRYZE was only considered as a rescue medication when treated for breakthrough attack treatment. For historical data, only medications taken prior to the start of drug study drug administration and had an indication of "hereditary angioedema (HAE) management - acute treatment" selected on the prior and concomitant medications and therapy were considered as rescue medications. Historical data was obtained from medical or angioedema history eCRF.', 'unitOfMeasure': 'Angioedema attacks per month', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants Achieving Clinical Responder Rate Relative to Historical Data', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Achieving >= 50% reduction in NNA', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Achieving >= 70% reduction in NNA', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}]}]}, {'title': 'Achieving >= 90% reduction in NNA', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 12', 'description': 'Number of participants achieving at least 50 percent (%), 70% or 90% reduction in NNA relative to NNA for historical data was reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Change From Baseline in Angioedema Quality of Life (AE-QoL) in Treatment Period', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Total Score (Baseline)', 'categories': [{'measurements': [{'value': '28.3', 'spread': '12.79', 'groupId': 'OG000'}]}]}, {'title': 'Total Score (Change from baseline)', 'categories': [{'measurements': [{'value': '-9.0', 'spread': '16.72', 'groupId': 'OG000'}]}]}, {'title': 'Functioning (Baseline)', 'categories': [{'measurements': [{'value': '16.4', 'spread': '11.54', 'groupId': 'OG000'}]}]}, {'title': 'Functioning (Change from baseline)', 'categories': [{'measurements': [{'value': '-2.3', 'spread': '22.39', 'groupId': 'OG000'}]}]}, {'title': 'Fatigue/Mood (Baseline)', 'categories': [{'measurements': [{'value': '18.8', 'spread': '19.59', 'groupId': 'OG000'}]}]}, {'title': 'Fatigue/Mood (Change from baseline)', 'categories': [{'measurements': [{'value': '-9.4', 'spread': '14.00', 'groupId': 'OG000'}]}]}, {'title': 'Fears/Shame (Baseline)', 'categories': [{'measurements': [{'value': '49.5', 'spread': '21.76', 'groupId': 'OG000'}]}]}, {'title': 'Fears/Shame (Change from baseline)', 'categories': [{'measurements': [{'value': '-14.1', 'spread': '21.12', 'groupId': 'OG000'}]}]}, {'title': 'Nutrition (Baseline)', 'categories': [{'measurements': [{'value': '12.5', 'spread': '16.37', 'groupId': 'OG000'}]}]}, {'title': 'Nutrition (Change from baseline)', 'categories': [{'measurements': [{'value': '-6.3', 'spread': '24.09', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12', 'description': "Angioedema quality of life (AE-QoL) questionnaire was a self-administered validated angioedema disease-specific quality of life instrument. It consisted of 17 specific questions that were associated with work, physical activity, free time, social relations, and diet. Each of the 17 items had a 5-point response scale ranging from 1 (Never) to 5 (Very Often). The questionnaire was scored according to the developers' guidelines to produce a total score and 4 domain scores (functioning, fatigue/mood, fear/shame, nutrition). Raw domain scores (mean of the item scores within each scale) and the raw total score (mean of all item scores) were rescaled using linear transformations into final percentage scores ranging 0 to 100, based on the maximum possible score, where the higher the score the greater the QoL impairment.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Breakthrough Angioedema Attacks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Treated (CINRYZE)', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Untreated', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}, {'title': 'Treated (CINRYZE): One BAA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Treated (CINRYZE): Two BAA', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Treated (CINRYZE): Three BAA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH): One BAA', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH): Two BAA', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH): Three BAA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Untreated: One BAA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Untreated: Two BAA', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Untreated: Three BAA', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}]}]}, {'title': 'Treated (CINRYZE): Initial improvement', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH): Initial improvement', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Untreated: Initial improvement', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}, {'title': 'Treated (CINRYZE): Complete resolution', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}, {'title': 'Treated (NON-CINRYZE C1 INH): Complete resolution', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Untreated: Complete resolution', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 12', 'description': 'A breakthrough attack was defined as an angioedema attack that occurs during long-term prevention therapy with CINRYZE (that is, between first study drug and last study drug dose). Number of participants with 1, 2, 3 or more angioedema attacks and who achieved initial improvement and complete resolution were also reported. Breakthrough angioedema attacks assessed by CINRYZE treatment, non-CINRYZE C1 INH treatment and untreated with C1-INH were reported. Here BAA refers to breakthrough angioedema attacks.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment. Number of participants evaluable for this outcome measure was reported.'}, {'type': 'PRIMARY', 'title': 'Time From Attack Onset to Initial Improvement and Complete Resolution', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'title': 'Treated (CINRYZE): TII', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '13.38', 'groupId': 'OG000', 'lowerLimit': '4.250', 'upperLimit': '22.500'}]}]}, {'title': 'Treated (NON-CINRYZE): TII', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.42', 'comment': '95% confidence interval lower and upper limits was not calculated due to insufficient number of participants.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Untreated: TII', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.75', 'groupId': 'OG000', 'lowerLimit': '8.750', 'upperLimit': '118.000'}]}]}, {'title': 'Treated (CINRYZE): Complete resolution', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '40.67', 'groupId': 'OG000', 'lowerLimit': '23.834', 'upperLimit': '57.500'}]}]}, {'title': 'Treated (NON-CINRYZE): Complete resolution', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '9.00', 'comment': '95% confidence interval lower and upper limits was not calculated due to insufficient number of participants.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Untreated: Complete resolution', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '61.83', 'groupId': 'OG000', 'lowerLimit': '11.000', 'upperLimit': '152.000'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'Time to initial improvement (TII) was calculated from the time of study drug administration to initial symptom improvement. Time to complete resolution was defined as the time from the onset of attack to complete resolution of all symptoms. Time to initial improvement and time to complete resolution as assessed by CINRYZE, non-CINRYZE and untreated were reported.', 'unitOfMeasure': 'Hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment. Number of participants evaluable for this outcome were reported.'}, {'type': 'PRIMARY', 'title': 'Time From Onset of Attack to Time Treated by CINRYZE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.97', 'groupId': 'OG000', 'lowerLimit': '3.050', 'upperLimit': '20.884'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'The median time from onset of attack to time treated with CINRYZE was reported.', 'unitOfMeasure': 'Hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 postbaseline efficacy assessment.'}, {'type': 'PRIMARY', 'title': 'Time From Treatment With CINRYZE to Initial Improvement', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.41', 'groupId': 'OG000', 'lowerLimit': '1.200', 'upperLimit': '1.617'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Week 12', 'description': 'Time to initial improvement was calculated from the time of study drug administration to initial symptom improvement. Median time from treatment with CINRYZE to initial improvement was reported.', 'unitOfMeasure': 'Hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who had at least 1 post-baseline efficacy assessment.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CINRYZE 500 U', 'description': 'Participants received 500 U CINRYZE intravenous (IV) injection twice weekly for 12 weeks.'}, {'id': 'FG001', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'The study was conducted in 9 study centers in Japan between 13 Sep 2016 (First participant first visit) and 23 June 2017 (Last participant last visit).', 'preAssignmentDetails': "A total of 8 participants were screened and enrolled. Investigational product administrations were planned according to participants' age; 500 units (U) for participants 2 to 5 years and 1000 U for participants 6 years and older. However, as no participants under the age of 6 years were enrolled, only the higher dose of 1000 U was administered."}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'CINRYZE 500 U', 'description': 'Participants received 500 U CINRYZE IV injection twice weekly for 12 weeks.'}, {'id': 'BG001', 'title': 'CINRYZE 1000 U', 'description': 'Participants received 1000 U CINRYZE IV injection twice weekly for 12 weeks.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '38.4', 'spread': '7.27', 'groupId': 'BG001'}, {'value': '38.4', 'spread': '7.27', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'year', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Intent-to-treat safety (ITT-S) set included participants who received any amount of investigational product.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-08-30', 'size': 3450083, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-06-20T08:43', 'hasProtocol': True}, {'date': '2017-07-21', 'size': 6575097, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-06-20T08:44', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 8}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-09-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-05', 'completionDateStruct': {'date': '2017-06-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-05-13', 'studyFirstSubmitDate': '2016-08-09', 'resultsFirstSubmitDate': '2018-06-20', 'studyFirstSubmitQcDate': '2016-08-09', 'lastUpdatePostDateStruct': {'date': '2021-06-02', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-06-20', 'studyFirstPostDateStruct': {'date': '2016-08-12', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-12-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-06-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'From start of study drug administration up to Week 12', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with the treatment. TEAEs were defined as all AEs that started during the treatment period and up to 7 days after the last dose of investigational product, or AEs that were seen at baseline but worsened in frequency and/or severity during the treatment period and up to 7 days after the last dose of investigational product.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Physical Examination Reported as Adverse Events (AEs)', 'timeFrame': 'From start of study drug administration up to Week 12', 'description': 'Physical examinations included measurement of body weight and height. Clinically significant abnormalities related to physical examination as determined by investigator were recorded and reported as AE.'}, {'measure': 'Number of Participants With Potentially Clinically Important (PCI) Vital Signs Reported as Adverse Events (AEs)', 'timeFrame': 'Baseline up to Week 12', 'description': "Vital sign assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate. Investigator used both absolute values and change from baseline values to determine if the vital sign was potentially clinically important. Criteria for the potential clinical importance of both absolute and change from baseline values were pre-specified as: SBP (less than \\[\\<\\] 90 millimeter of mercury \\[mmHg\\]; greater than or equal to \\[\\>=\\] 140 mmHg), DBP (\\< 60 mmHg; \\>=90 mmHg) and pulse (less than or equal to \\[\\<=\\] 50 beats per minute \\[bpm\\]; \\>= 100 bpm. A participant's vital sign had to meet both the absolute and change from baseline criteria to be considered as potentially clinically important."}, {'measure': 'Number of Participants With Potentially Clinically Important (PCI) Clinical Laboratory Assessments Reported as Adverse Events (AEs)', 'timeFrame': 'Baseline up to Week 12', 'description': 'Number of participants with potentially clinically important (PCI) clinical laboratory assessments reported as adverse events were reported.'}, {'measure': 'Concentration of C1 Esterase Inhibitor (C1 INH) Antigen (Protein Volume) at Week 1', 'timeFrame': 'Week 1: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 hours (h) post-dose', 'description': 'C1 INH antigen concentration in plasma was determined using an automated nephelometric assay.'}, {'measure': 'Concentration of C1 Esterase Inhibitor (C1 INH) Antigen (Protein Volume) at Week 12', 'timeFrame': 'Week 12: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'C1 INH antigen concentration in plasma was determined using an automated nephelometric assay.'}, {'measure': 'Concentration of Plasma Complement C4 at Week 1', 'timeFrame': 'Week 1: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'Concentration of plasma complement C4 was reported.'}, {'measure': 'Concentration of Plasma Complement C4 at Week 12', 'timeFrame': 'Week 12: Pre-dose, 0.5, 1, 2, 6, 24, 48, 72 and 96 h post-dose', 'description': 'Concentration of plasma complement C4 was reported.'}, {'measure': 'Concentration of Plasma Complement C1q at Week 1', 'timeFrame': 'Baseline (Week 1)', 'description': 'Concentration of plasma complement C1q was reported.'}, {'measure': 'Normalized Number of Angioedema Attacks (NNA) Per Month', 'timeFrame': 'Baseline up to Week 12', 'description': 'Angioedema attack was defined as any participant-reported (or caregiver-reported) indication of swelling or pain at any location following a report of no swelling or pain on the previous day (that is, there must have been a full symptom-free calendar day preceding the onset of symptoms for an attack to be considered a new attack). NNA was calculated as the overall number of angioedema attacks recorded during the period divided by the number of days in the period and multiplied by 30.4.Number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency as compared to the historical data where, NNA was the number of angioedema attacks during 3 months prior to study drug administration. Historical data was obtained from medical or angioedema history electronic case report forms (eCRF).'}, {'measure': 'Number of Participants With Angioedema Attacks in Different Anatomic Locations', 'timeFrame': 'Baseline up to Week 12', 'description': "Anatomic locations where there was a presence of pain or swelling of any level of severity; mild, moderate or severe at any day during the attack were reported. Mild: the attack symptoms were noticeable but were easily tolerated by the participant and did not interfere with the participant's daily activities. Moderate: the attack symptoms interfered with the participant's ability to attend work/school or participate in family life and social/recreational activities and severe: the attack symptoms significantly limited the participant's ability to attend work/school or participate in family life and social/recreational activities. Number of participants with angioedema attacks in different anatomic locations in treatment period was compared to NNA for historical data. Historical data was based on the typical location of angioedema attacks in the 3 months prior to study drug administration. Here, H refers to historical and T refers to treatment."}, {'measure': 'Average Severity (Intensity) of Angioedema Attacks', 'timeFrame': 'Baseline up to Week 12', 'description': 'All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the participant to any swelling location on any day during the attack. The average severity was derived by dividing the cumulative severity score by the total number of attacks. Average severity was set to 0 if there was no attack in a period. Average severity of angioedema attacks in treatment period compared to the NNA of angioedema attacks for historical data was reported. Historical data was based on the typical severity of angioedema attacks in the 3 months prior to study drug administration. Historical data was obtained from medical or angioedema history electronic case report forms (eCRF).'}, {'measure': 'Average Duration of Angioedema Attacks', 'timeFrame': 'Baseline up to Week 12', 'description': 'Average duration of attacks was calculated by dividing the cumulative duration of attacks by the total number of attacks during the treatment period. Historical data was based on the typical severity of angioedema attacks in the 3 months prior to study drug administration. Average duration of angioedema attacks in treatment period was compared to the NNA for historical data. Historical data was obtained from medical or angioedema history eCRF.'}, {'measure': 'Normalized Number of Angioedema Attacks (NNA) Per Month Treated With Rescue Medication', 'timeFrame': 'Baseline up to Week 12', 'description': 'The normalized number of angioedema attacks was calculated as the overall number of angioedema attacks recorded during the period divided by the number of days in the period and multiplied by 30.4. NNA treated with rescue medications were reported for CINRYZE, non-CINRYZE C1-INH or not treated with C1-INH (including attacks treated with any medications other than C1-INH or untreated attacks). CINRYZE was only considered as a rescue medication when treated for breakthrough attack treatment. For historical data, only medications taken prior to the start of drug study drug administration and had an indication of "hereditary angioedema (HAE) management - acute treatment" selected on the prior and concomitant medications and therapy were considered as rescue medications. Historical data was obtained from medical or angioedema history eCRF.'}, {'measure': 'Number of Participants Achieving Clinical Responder Rate Relative to Historical Data', 'timeFrame': 'Baseline up to Week 12', 'description': 'Number of participants achieving at least 50 percent (%), 70% or 90% reduction in NNA relative to NNA for historical data was reported.'}, {'measure': 'Change From Baseline in Angioedema Quality of Life (AE-QoL) in Treatment Period', 'timeFrame': 'Baseline, Week 12', 'description': "Angioedema quality of life (AE-QoL) questionnaire was a self-administered validated angioedema disease-specific quality of life instrument. It consisted of 17 specific questions that were associated with work, physical activity, free time, social relations, and diet. Each of the 17 items had a 5-point response scale ranging from 1 (Never) to 5 (Very Often). The questionnaire was scored according to the developers' guidelines to produce a total score and 4 domain scores (functioning, fatigue/mood, fear/shame, nutrition). Raw domain scores (mean of the item scores within each scale) and the raw total score (mean of all item scores) were rescaled using linear transformations into final percentage scores ranging 0 to 100, based on the maximum possible score, where the higher the score the greater the QoL impairment."}, {'measure': 'Number of Participants With Breakthrough Angioedema Attacks', 'timeFrame': 'Baseline up to Week 12', 'description': 'A breakthrough attack was defined as an angioedema attack that occurs during long-term prevention therapy with CINRYZE (that is, between first study drug and last study drug dose). Number of participants with 1, 2, 3 or more angioedema attacks and who achieved initial improvement and complete resolution were also reported. Breakthrough angioedema attacks assessed by CINRYZE treatment, non-CINRYZE C1 INH treatment and untreated with C1-INH were reported. Here BAA refers to breakthrough angioedema attacks.'}, {'measure': 'Time From Attack Onset to Initial Improvement and Complete Resolution', 'timeFrame': 'Baseline up to Week 12', 'description': 'Time to initial improvement (TII) was calculated from the time of study drug administration to initial symptom improvement. Time to complete resolution was defined as the time from the onset of attack to complete resolution of all symptoms. Time to initial improvement and time to complete resolution as assessed by CINRYZE, non-CINRYZE and untreated were reported.'}, {'measure': 'Time From Onset of Attack to Time Treated by CINRYZE', 'timeFrame': 'Baseline up to Week 12', 'description': 'The median time from onset of attack to time treated with CINRYZE was reported.'}, {'measure': 'Time From Treatment With CINRYZE to Initial Improvement', 'timeFrame': 'Baseline up to Week 12', 'description': 'Time to initial improvement was calculated from the time of study drug administration to initial symptom improvement. Median time from treatment with CINRYZE to initial improvement was reported.'}]}, 'conditionsModule': {'conditions': ['Hereditary Angioedema (HAE)']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '2 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents.\n2. Be ≥2 years of age.\n3. Meet the following minimum body weight criteria:\n\n * Subjects 2 to 5 years of age must weigh at least 12.5 kg; and\n * Subjects 6 years of age and above must weigh at least 25 kg.\n4. Have a confirmed diagnosis of Type I or Type II HAE. NOTE: Diagnosis may be based on historical data including family history, clinical symptoms (characteristic attacks), or documentation of low level of C1 INH protein and/or C1 INH activity.\n5. Have a history of at least one angioedema attack per month (on average) during the 3 consecutive months immediately before enrollment.\n6. Agree to adhere to the protocol-defined schedule of assessments and procedures.\n7. Agree to avoid his/her known angioedema attack triggers during the study to the best of his/her ability.\n8. If a female of reproductive age, be postmenopausal (≥12 months following cessation of menstruation), surgically sterile, or following an acceptable method of birth control (and agree to continue its use through 1 month after the last dose of study drug):\n\n * Non-hormonal methods (eg, abstinence, barrier control) for at least 1 complete menstrual cycle before the Screening Visit.\n * Stable doses of estrogen and/or progestin containing products for at least 2 months before the Screening Visit.\n9. If a male of reproductive age, be surgically sterile or agree to follow an acceptable method of birth control (eg, abstinence, barrier control) from the Screening Visit through 2 months after the last dose of study drug.\n10. If an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.\n\nOR If a child or minor (\\<20 years of age), have a parent/legal guardian who is informed of the nature of the study provide written informed consent (ie, permission) for the child to participate in the study before any study-specific procedures are performed. Assent will be obtained from children ≥14 years of age.\n\nExclusion Criteria:\n\n1. Have a history of hypercoagulability (abnormal blood clotting).\n2. Have a diagnosis of acquired angioedema or be known to have C1 INH antibodies.\n3. Have a history of allergic reaction to C1 INH products, including CINRYZE (or any of the components of CINRYZE) or other blood products.\n4. Have received C1 INH therapy or any blood products within 3 days before the first dose of study drug.\n5. Have had signs or symptoms of an angioedema attack within 2 days before the first dose of study drug.\n6. Have any change (start, stop, or change in dose) in androgen therapy (eg, danazol, oxandrolone, stanozolol, testosterone), tranexamic acid, epsilon-aminocaproic acid (EACA), or other antifibrinolytics within 14 days before the first dose of study drug.\n7. If female, have started taking or changed the dose of any hormonal contraceptive regimen or hormone replacement therapy (eg, estrogen/progestin containing products) within 2 months before the first dose of study drug.\n8. Be pregnant or breastfeeding.\n9. Have received an investigational drug other than those required for prevention or treatment of angioedema attacks within 30 days before the first dose of study drug.\n10. Have, as determined by the Investigator and/or the Sponsor's Medical Monitor, any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results."}, 'identificationModule': {'nctId': 'NCT02865720', 'briefTitle': 'Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Takeda'}, 'officialTitle': 'A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)', 'orgStudyIdInfo': {'id': 'SHP616-209'}, 'secondaryIdInfos': [{'id': '0624-209', 'type': 'OTHER', 'domain': 'Shire'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Subjects 2 to 5 years of age', 'description': '500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks', 'interventionNames': ['Drug: CINRYZE 500 U']}, {'type': 'EXPERIMENTAL', 'label': 'Subjects 6 years of age and older', 'description': '1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.', 'interventionNames': ['Drug: CINRYZE 1000 U']}], 'interventions': [{'name': 'CINRYZE 500 U', 'type': 'DRUG', 'description': 'IV infusion administered twice weekly', 'armGroupLabels': ['Subjects 2 to 5 years of age']}, {'name': 'CINRYZE 1000 U', 'type': 'DRUG', 'description': 'IV infusion administered twice weekly', 'armGroupLabels': ['Subjects 6 years of age and older']}]}, 'contactsLocationsModule': {'locations': [{'zip': '441-8570', 'city': 'Toyohashi', 'state': 'Aiti', 'country': 'Japan', 'facility': 'Toyohashi Municipal Hospital', 'geoPoint': {'lat': 34.76667, 'lon': 137.38333}}, {'zip': '289-2511', 'city': 'Asahi', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Asahi General Hospital', 'geoPoint': {'lat': 35.71667, 'lon': 140.65}}, {'zip': '371-8511', 'city': 'Maebashi', 'state': 'Gunma', 'country': 'Japan', 'facility': 'Gunma University Hospital', 'geoPoint': {'lat': 36.4, 'lon': 139.08333}}, {'zip': '650-0017', 'city': 'Kobe', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Kobe University Hospital', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'zip': '901-2417', 'city': 'Nakagusuku', 'state': 'Nakagami', 'country': 'Japan', 'facility': 'Heart Life Hospital', 'geoPoint': {'lat': 26.25, 'lon': 127.78333}}, {'zip': '902-8511', 'city': 'Naha', 'state': 'Okinawa', 'country': 'Japan', 'facility': 'Naha City Hospital', 'geoPoint': {'lat': 26.213, 'lon': 127.67851}}, {'zip': '693-8501', 'city': 'Izumo', 'state': 'Shimane', 'country': 'Japan', 'facility': 'Shiman University Hospital', 'geoPoint': {'lat': 35.36667, 'lon': 132.76667}}, {'zip': '120-0022', 'city': 'Adachi City', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Adachi kyosai Hospital', 'geoPoint': {'lat': 35.76318, 'lon': 139.80761}}, {'zip': '734-8551', 'city': 'Hiroshima', 'country': 'Japan', 'facility': 'Hiroshima University Hospital', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'zip': '053-8567', 'city': 'Tomakomai', 'country': 'Japan', 'facility': 'Tomakomai City Hospital', 'geoPoint': {'lat': 42.63694, 'lon': 141.60333}}], 'overallOfficials': [{'name': 'Study Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Takeda'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/takeda/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'ipdSharing': 'YES', 'description': "Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.", 'accessCriteria': 'IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shire', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}